Mark Connor

25PUBLICATIONS
65CO-AUTHORS
Biologically active moleculesCharacterisation of biological macromoleculesCheminformatics and quantitative structure-activity relationshipsPharmacogenomicsNanophotonics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Sep 16, 2026
(+)-Trans-Cannabidiol Is an Agonist at Human CB2 Receptors.

|Aug 13, 2024
Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene.

Michael Udoh, Marina Santiago, Syed Haneef

|May 27, 2024
Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations.

Tahira Foyzun, Maddie Whiting, Kate K Velasco

|Jul 27, 2023
Synthesis and Preclinical Evaluation of Fluorinated 5-Azaindoles as CB2 PET Radioligands.

Annukka Kallinen, Karine Mardon, Samuel Lane

|Apr 20, 2022
Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (CaV3) Inhibitors.

Richard C Kevin, Somayeh Mirlohi, Jamie J Manning

|Apr 11, 2022
Defining Steric Requirements at CB1 and CB2 Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues.

Jack Markham, Eric Sparkes, Rochelle Boyd

Pageof 5

Frequent Collaborators

7 joint publications

Marina Santiago

7 joint publications

Samuel D Banister

6 joint publications

Michelle Glass

4 joint publications

Michael Kassiou